Back to Search
Start Over
Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK
- Source :
- Journal of Clinical Oncology. 36:e16578-e16578
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- e16578Background: The randomised phase III METEOR trial showed survival benefit of cabozantinib over everolimus in patients with mRCC who progressed after VEGF targeted therapy. We report real worl...
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Cabozantinib
medicine.medical_treatment
VEGF receptors
urologic and male genital diseases
Targeted therapy
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Renal cell carcinoma
Internal medicine
medicine
In patient
Everolimus
biology
business.industry
medicine.disease
030104 developmental biology
Survival benefit
chemistry
030220 oncology & carcinogenesis
biology.protein
business
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........72c458c3a86e70081b3f740b258757a8
- Full Text :
- https://doi.org/10.1200/jco.2018.36.15_suppl.e16578